VivoSim Labs Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Public

  • Employees
  • 11

Employees

  • Stock Symbol
  • VIVS

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $0.13
  • (As of Friday Closing)

VivoSim Labs General Information

Description

VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.

Contact Information

Website
www.vivosim.ai
Formerly Known As
Organovo
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 11555 Sorrento Valley Road
  • Suite 100
  • San Diego, CA 92121
  • United States
+1 (858)
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 11555 Sorrento Valley Road
  • Suite 100
  • San Diego, CA 92121
  • United States
+1 (858)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

VivoSim Labs Stock Performance

As of 13-Nov-2026, VivoSim Labs’s stock price is $0.13. Its current market cap is $2.58M with 20.3M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.13 $0.14 $0.12 - $3.40 $2.58M 20.3M 1M -$4.47

VivoSim Labs Financials Summary

As of 30-Jun-2026, VivoSim Labs has a trailing 12-month revenue of $112K.

In Thousands,
USD
TTM 30-Jun-2026 FY 2026 31-Mar-2026 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024
EV (614) 18 3,931 6,547
Revenue 112 131 144 109
EBITDA (12,346) (13,881) (2,350) (14,794)
Net Income (12,338) (13,843) (2,488) (14,671)
Total Assets 3,847 7,386 14,650 6,349
Total Debt 316 447 942 1,394
Public Fundamental Data provided by Morningstar, Inc. disclaimer

VivoSim Labs Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore VivoSim Labs‘s full profile, request access.

Request a free trial

VivoSim Labs Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in
Biotechnology
San Diego, CA
11 As of 2026

Vancouver, Canada
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

VivoSim Labs Competitors (35)

One of VivoSim Labs’s 35 competitors is Aspect Biosystems, a Venture Capital-Backed company based in Vancouver, Canada.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aspect Biosystems Venture Capital-Backed Vancouver, Canada
WaVe Life Sciences Formerly VC-backed Cambridge, MA
Byondis Corporation Nijmegen, Netherlands
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Halozyme Therapeutics Formerly VC-backed San Diego, CA
You’re viewing 5 of 35 competitors. Get the full list »

VivoSim Labs Patents

VivoSim Labs Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3171987-A1 Crystalline forms of a farnesoid x receptor agonist Pending 18-Mar-2020
CA-3172205-A1 Farnesoid x receptor agonists for the treatment of disease Pending 18-Mar-2020
CA-3112411-A1 Farnesoid x receptor agonists and uses thereof Pending 18-Sep-2018
US-20230382913-A1 Farnesoid x receptor agonists and uses thereof Inactive 18-Sep-2018
WO-2019227063-A1 Methods, assays, and kits for evaluating the performance of engineered liver tissue constructs Inactive 25-May-2018 A61B5/15003
To view VivoSim Labs’s complete patent history, request access »

VivoSim Labs Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

VivoSim Labs Investments & Acquisitions (2)

VivoSim Labs’s most recent deal was a Corporate Asset Purchase with Organovo (FXR Program and Related Assets in San Ramon, California) for . The deal was made on 10-Mar-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Organovo (FXR Program and Related Assets in San Ramon, California) 10-Mar-2023 Corporate Asset Purchase Buildings and Property
VivoSim Labs 08-Feb-2012 Reverse Merger Biotechnology
To view VivoSim Labs’s complete investments and acquisitions history, request access »

VivoSim Labs ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view VivoSim Labs’s complete esg history, request access »

VivoSim Labs Exits (2)

VivoSim Labs’s most recent exit was on 10-Mar-2023 from Organovo (FXR Program and Related Assets in San Ramon, California). The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Organovo (FXR Program and Related Assets in San Ramon, California) 10-Mar-2023 Completed
VivoSim Labs 08-Feb-2012 Reverse Merger Completed
To view VivoSim Labs’s complete exits history, request access »

VivoSim Labs FAQs

  • When was VivoSim Labs founded?

    VivoSim Labs was founded in 2007.

  • Where is VivoSim Labs headquartered?

    VivoSim Labs is headquartered in San Diego, CA.

  • What is the size of VivoSim Labs?

    VivoSim Labs has 11 total employees.

  • What industry is VivoSim Labs in?

    VivoSim Labs’s primary industry is Biotechnology.

  • Is VivoSim Labs a private or public company?

    VivoSim Labs is a Public company.

  • What is VivoSim Labs’s stock symbol?

    The ticker symbol for VivoSim Labs is VIVS.

  • What is the current stock price of VivoSim Labs?

    As of 13-Nov-2026 the stock price of VivoSim Labs is $0.13.

  • What is the current market cap of VivoSim Labs?

    The current market capitalization of VivoSim Labs is $2.58M.

  • What is VivoSim Labs’s current revenue?

    The trailing twelve month revenue for VivoSim Labs is $112K.

  • Who are VivoSim Labs’s competitors?

    Aspect Biosystems, WaVe Life Sciences, Byondis, CytomX Therapeutics, and Halozyme Therapeutics are some of the 35 competitors of VivoSim Labs.

  • What is VivoSim Labs’s annual earnings per share (EPS)?

    VivoSim Labs’s EPS for 12 months was -$4.47.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process